Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately ...

Biosimilars including Filgrastim and Bevacizumab will be launched in Europe by July 2025. Aurobindo's China plant, with an ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Avastin (bevacizumab) is a prescription drug used to treat certain types of cancer. Avastin is also available as a biosimilar drug. It’s prescribed for adults ages 18 years and older.

“We are proud to achieve the approval of the first biosimilar to omalizumab in the U.S., which will help broaden access to this important medicine for patients with allergic and respiratory conditions ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

But that average obscures some wide, molecule by molecule, variation. While four biosimilars to Avastin (bevacizumab) have gained 89% of market share six years after the first one launched and the ...